Thus, in addition to demonstrating the activity of lapatinib plus paclitaxel, the TyTAN study also made crucial observations that have brought us closer to devising standardized guidelines for HER2 IHC status positivity in gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.